Hvivo (HVO)

Sector:

Health Care

Index:

FTSE AIM All-Share

15.00p
   
  • Change Today:
    -0.100p
  • 52 Week High: 21.63
  • 52 Week Low: 8.75
  • Currency: UK Pounds
  • Shares Issued: 678.76m
  • Volume: 852,615
  • Market Cap: 101.81m

Open Orphan wins 7.2m contract for RSV human study

By Josh White

Date: Tuesday 14 Jun 2022

LONDON (ShareCast) - (Sharecast News) - Contract research organisation Open Orphan announced on Tuesday that iits subsidiary hVIVO has signed a 7.2m contract with an existing global pharmaceutical company to test its orally-administered antiviral product using its human challenge study model for respiratory syncytial virus (RSV).
The AIM-traded firm said the phase 2a double-blinded placebo-controlled human challenge study would take place at its specialist quarantine facilities in Whitechapel, and would evaluate the safety and efficacy profile of the antiviral against RSV.

It said the study would start in June, with the revenue being recognised in 2022 and 2023.

As part of the study, hVIVO would recruit healthy volunteers via its dedicated volunteer recruitment arm, FluCamp.

The client's antiviral was currently in phase 3 clinical trials for another infectious disease indication, with the client set to use human challenge to assess the efficacy of the drug candidate against RSV "quickly and efficiently".

Open Orphan said the repeat business from the "top five" global pharmaceutical company underlined its expertise and ability to attract additional contracts from existing big pharma clients.

"We're delighted to be working with this top five global pharmaceutical client again to test their antiviral candidate using the hVIVO RSV human challenge study model," said chief executive officer Mo Khan.

"I am especially proud that our world-class offering and customer service has secured repeat business from another big pharma client, and that we are seen as the 'go-to' partner for an increasing number of global drug developers.

"The client's drug has already been shown to be an effective antiviral in certain disease indications, and we're pleased to now test its efficacy against RSV infection."

At 1516 BST, shares in Open Orphan were up 2.04% at 12.5p.

Reporting by Josh White at Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Hvivo Market Data

Currency UK Pounds
Share Price 15.00p
Change Today -0.100p
% Change -0.66 %
52 Week High 21.63
52 Week Low 8.75
Volume 852,615
Shares Issued 678.76m
Market Cap 101.81m

Hvivo Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
46.54% above the market average46.54% above the market average46.54% above the market average46.54% above the market average46.54% above the market average
48.72% above the sector average48.72% above the sector average48.72% above the sector average48.72% above the sector average48.72% above the sector average
Income Not Available
Growth
40.56% above the market average40.56% above the market average40.56% above the market average40.56% above the market average40.56% above the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average

What The Brokers Say

Strong Buy 1
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Hvivo Dividends

No dividends found

Trades for 30-Mar-2023

Time Volume / Share Price
16:35 10,106 @ 15.00p
16:35 106 @ 15.00p
16:35 9,894 @ 15.00p
16:35 106 @ 15.00p
16:35 1,000 @ 15.20p

Hvivo Key Personnel

CFO Leo Toole
CEO Yamin Mo' Khan

Top of Page